HELIA – A revolutionary technology for continuous biomarker monitoring in healthcare

Researchers at Eindhoven University of Technology have patented and demonstrated world’s first platform technology to continuously measure biomolecules at low concentrations. Sensors for continuous monitoring are commercially available for glucose, but not for other important substances such as hormones, peptides, proteins, and drugs, which have concentrations in blood that are orders of magnitude lower. HELIA Biomonitoring has the mission to develop the new technology into a platform for continuous biomolecular monitoring for healthcare applications. The first product that HELIA wants to target is the monitoring of patients in immuno-therapeutic, intensive-care, and peri-operative settings. The sensor can potentially serve millions of patients per year, for reducing morbidity, mortality and for saving healthcare costs. HELIA has a strong project team, with expertise in technology, product development, entrepreneurship, and healthcare, all determined to develop the platform for the benefit of patients. This Take-Off Phase 2 project will enable HELIA to build a prototype and develop the company, to a level where strategic partners will step on board to invest in the company or license and/or acquire the technology or parts of it.

  • Projectnummer / Project number: 17479
  • Projectleider / Project leader: Prof. dr. ir. M. W. J. Prins - HELIA Biomonitoring B.V
  • Type project / Type project: Lopend
  • Startdatum / Start date: 01-04-2019
  • Programma / Programme: Take-off
  • Vakgebied / Discipline: Scheikunde